Avience Biomedicals SME IPO GMP History
Avience Biomedicals SME IPO has been listed on June 25, 2026 at a listing price of ₹395.20, against the issue price of ₹208 — a gain of ₹187.2 (+90%). The GMP peaked at ₹145 on 25 June 2026 and reached a low of ₹63 on 16 June 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Avience Biomedicals SME IPO raised ₹30.24 Cr. through its IPO at a price band of ₹196 to ₹208 per share, with a lot size of 600 shares. The IPO was open for subscription from 18 Jun 2026 to 22 Jun 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 25 Aug, 12:54 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 25 Jun 2026 | ₹ 145 | ▲ | 69.7% | — | — |
| 24 Jun 2026 | ₹ 130 | ▲ | 62.5% | — | — |
| 23 Jun 2026 | ₹ 95 | ▲ | 45.7% | — | — |
| 22 Jun 2026 | ₹ 72 | ▲ | 34.6% | — | — |
| 21 Jun 2026 | ₹ 70 | ▼ | 33.7% | — | — |
| 20 Jun 2026 | ₹ 85 | — | 40.9% | — | — |
| 19 Jun 2026 | ₹ 85 | — | 40.9% | — | — |
| 18 Jun 2026 | ₹ 85 | ▲ | 40.9% | — | — |
| 17 Jun 2026 | ₹ 75 | ▲ | 36.1% | — | — |
| 16 Jun 2026 | ₹ 63 | ▼ | 30.3% | — | — |
| 15 Jun 2026 | ₹ 70 | — | 33.7% | — | — |
Avience Biomedicals SME IPO dates
Key dates from opening to listing. Today is 11 October.
- Open 18 Jun 2026
- Close 22 Jun 2026
- Allotment 23 Jun 2026
- Refund/credit 24 Jun 2026
- Listing 25 Jun 2026
Avience Biomedicals SME IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹208 |
|---|---|
| GMP-based estimate (pre-listing) | ₹353 (+69.7%) |
| Listing gain / loss | +₹187.2 per share |
| Listing date | 25 Jun, 2026 |
| Actual listing price | ₹395.20 (+90%) |
Is Avience Biomedicals SME IPO GMP reliable?
Grey market premium for Avience Biomedicals SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Avience Biomedicals SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Avience Biomedicals SME IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Avience Biomedicals SME IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Avience Biomedicals SME IPO
Avience Biomedicals Limited was incorporated in 2019 as Avience Biomedicals Private Limited and was later converted into a public limited company. The company is promoted by Dharam Deo Choudhary, Ram Nagina Choudhary, Janardan Pal and Deepa Choudhary. Headquartered in New Delhi, the company has established itself in the healthcare diagnostics segment by focusing on quality-driven biomedical and diagnostic products.
The company is engaged in the manufacturing and distribution of molecular diagnostic kits, reagents and related healthcare products used by hospitals, laboratories and diagnostic centres. Its business model is based on developing and supplying testing solutions that support disease detection and clinical diagnostics. With increasing demand for advanced healthcare testing infrastructure, the company aims to expand its product portfolio and market reach across India.
Frequently asked
What is the GMP of Avience Biomedicals SME IPO?
The current Grey Market Premium (GMP) of Avience Biomedicals SME IPO is ₹ 145.
What is the Kostak Price of Avience Biomedicals SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Avience Biomedicals SME IPO is not available.
What is the Subject to Sauda Price of Avience Biomedicals SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Avience Biomedicals SME IPO?
Avience Biomedicals SME IPO listed on June 25, 2026 at ₹395.20, against the issue price of ₹208 — a gain of +90%.
How did the GMP of Avience Biomedicals SME IPO trend before listing?
The GMP of Avience Biomedicals SME IPO was rising in its final days before listing. The GMP peaked at ₹145 on 25 June 2026. View the day-wise table above for the complete GMP history.
Explore Avience Biomedicals SME IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
